Pneumocystis jirovecii pneumonia associated with gemcitabine chemotherapy: experience at an Australian center and recommendations for targeted prophylaxis

References

• Gesto DS, Cerqueira NM, Fernandes PA, et al. Gemcitabine: a critical nucleoside for cancer therapy. Curr Med Chem 2012;19: 1076–1087.
   PubMed Web of Science ®Google Scholar
• Mini E, Nobili S, Caciagli B, et al. Cellular pharmacology of gemcitabine. Ann Oncol 2006;17(Suppl. 5):v7–v12.
   PubMed Web of Science ®Google Scholar
• Cardenes HR, Moore AM, Johnson CS, et al. A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer:a Hoosier Oncology Group study. Am J Clin Oncol 2011;34:460–465.
   PubMed Web of Science ®Google Scholar
• Sugiyama T, Hirose T, Nakashima M, et al. Evaluation of the efficacy and safety of the combination of gemcitabine and nedaplatin for elderly patients with advanced non-small-cell lung cancer. Oncology 2011;81:273–280.
   PubMed Web of Science ®Google Scholar
• Palmieri A, Valentinis L, Bazzano S, et al. Progressive multifocal leukoencephalopathy following chemotherapy for lung cancer. Neurol Sci 2011;32:683–685.
   PubMed Web of Science ®Google Scholar
• Seto T, Yamanaka T, Wasada I, et al. Phase I/II trial of gemcitabine plus oral TS-1 in elderly patients with advanced non-small cell lung cancer: thoracic oncology research group study 0502. Lung Cancer 2010;69:213–217.
   PubMed Web of Science ®Google Scholar
• Tamura M, Saraya T, Fujiwara M, et al. High-resolution computed tomography findings for patients with drug-induced pulmonary toxicity, with special reference to hypersensitivity pneumonitis-like patterns in gemcitabine-induced cases. Oncologist 2013;18:454–459.
   PubMed Web of Science ®Google Scholar
• Reid AB, Chen SC, Worth LJ. Pneumocystis jirovecii pneumonia in non-HIV-infected patients: new risks and diagnostic tools. Curr Opin Infect Dis 2011;24:534–544.
   PubMed Web of Science ®Google Scholar
• Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis 2002;34:1098–1107.
   PubMed Web of Science ®Google Scholar
• Sepkowitz KA, Brown AE, Telzak EE, et al. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 1992;267:832–837.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Hargis JB, Kester KE, et al. Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis. Am J Hematol 1995;49:135–142.
   PubMed Web of Science ®Google Scholar
• Bergmann L, Fenchel K, Jahn B, et al. Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Ann Oncol 1993;4:371–375.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Kobayashi Y, Asakura Y, et al. Pneumocystis jiroveci pneumonia in relation to CD4 + lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapy. Leuk Lymphoma 2010;51:1816–1821.
   PubMed Web of Science ®Google Scholar
• Gertler SZ, MacDonald D, Goodyear M, et al. NCIC-CTG phase II study of gemcitabine in patients with malignant glioma (IND.94). Ann Oncol 2000;11:315–318.
   PubMed Web of Science ®Google Scholar
• Worth LJ, Dooley MJ, Seymour JF, et al. An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital. Br J Cancer 2005;92:867–872.
   PubMed Web of Science ®Google Scholar
• Thursky KA, Worth LJ, Seymour JF, et al. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. Br J Haematol 2006;132:3–12.
   PubMed Web of Science ®Google Scholar
• Teh BW, Azzato FA, Lingaratnam SM, et al. Molecular diagnosis of Pneumocystis jirovecii in patients with malignancy: clinical significance of quantitative PCR. Med Mycol 2014 Feb 28. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Haeusler GM, Slavin MA, Seymour JF, et al. Late-onset Pneumocystis jirovecii pneumonia post fludarabine, cyclophosphamide and rituximab: implications for prophylaxis. Eur J Haematol 2013; 91:157–163.
   PubMed Web of Science ®Google Scholar
• Larsen HH, Masur H, Kovacs JA, et al. Development and evaluation of a quantitative, touch-down, real-time PCR assay for diagnosing Pneumocystis carinii pneumonia. J Clin Microbiol 2002;40:490–494.
   PubMed Web of Science ®Google Scholar
• Pavlakis N, Bell DR, Millward MJ, et al. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997;80: 286–291.
   PubMed Web of Science ®Google Scholar
• Barlesi F, Villani P, Doddoli C, et al. Gemcitabine-induced severe pulmonary toxicity. Fundam Clin Pharmacol 2004;18:85–91.
   PubMed Web of Science ®Google Scholar
• Tia T, Putaporntip C, Kosuwin R, et al. A highly sensitive novel PCR assay for detection of Pneumocystis jirovecii DNA in bronchoalveloar lavage specimens from immunocompromised patients. Clin Microbiol Infect 2012;18:598–603.
   PubMed Web of Science ®Google Scholar
• Morris A, Norris KA. Colonization by Pneumocystis jirovecii and its role in disease. Clin Microbiol Rev 2012;25:297–317.
   PubMed Web of Science ®Google Scholar
• Chen YG, Lin TY, Lin GM, et al. Pulmonary cryptococcus infection after mono-chemotherapy with gemcitabine. Respir Care 2011; 56:339–341.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Apetoh L, Ghiringhelli F, et al. The anticancer immune response: indispensable for therapeutic success? J Clin Invest 2008;118:1991–2001.
   PubMed Web of Science ®Google Scholar
• Plate JM, Plate AE, Shott S, et al. Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother 2005;54:915–925.
   PubMed Web of Science ®Google Scholar
• Mansharamani NG, Balachandran D, Vernovsky I, et al. Peripheral blood CD4 + T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest 2000;118:712–720.
   PubMed Web of Science ®Google Scholar
• Stilling-Vinther MK, Pedersen BS. Fatal Pneumocystis jirovecii pneumonia following immunosuppressive therapy with rituximab and prednisolone for posterior scleritis. Acta Ophthalmol 2012;90: e154–e155.
   PubMed Web of Science ®Google Scholar
• Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci 2007;52: 1481–1484.
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Kokura S, Sakamoto N, et al. Phase II trial of combined regional hyperthermia and gemcitabine for locally advanced or metastatic pancreatic cancer. Int J Hyperthermia 2012; 28:597–604.
   PubMed Web of Science ®Google Scholar
• Hui YF, Reitz J. Gemcitabine: a cytidine analogue active against solid tumors. Am J Health Syst Pharm 1997;54:162–170; quiz 197–168.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Kurzrock R, Freireich EJ, et al. 2-Chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4 + lymphocyte counts in patients with hairy cell leukemia. Blood 1994;83:2906–2911.
   PubMed Web of Science ®Google Scholar
• Ysebaert L, Gross E, Kuhlein E, et al. Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy. Leukemia 2010;24:1310–1316.
   PubMed Web of Science ®Google Scholar
• Green H, Paul M, Vidal L, et al. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2007;82:1052–1059.
   PubMed Web of Science ®Google Scholar
• Green H, Paul M, Vidal L, et al. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2007;(3):CD005590.
   Web of Science ®Google Scholar
• Nakazato T, Mihara A, Sanada Y, et al. Pneumocystis jiroveci pneumonia detected by FDG-PET. Ann Hematol 2010;89:839–840.
   PubMed Web of Science ®Google Scholar
• Ioannidis JP, Cappelleri JC, Skolnik PR, et al. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med 1996;156:177–188.
   PubMed Web of Science ®Google Scholar
• Magne D, Angoulvant A, Botterel F, et al. Pneumocystosis: a network survey in the Paris area 2003-2008. Eur J Clin Microbiol Infect Dis 2011;30:673–675.
   PubMed Web of Science ®Google Scholar
• Muller-Beissenhirtz H, Kasper C, Nuckel H, et al. Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, results of a phase II single center study. Ann Hematol 2005;84:796–801.
   PubMed Web of Science ®Google Scholar
• Sarris AH, Psyrri A, Hagemeister F, et al. Infusional vinorelbine in relapsed or refractory lymphomas. Leuk Lymphoma 2000;39: 291–299.
   PubMed Web of Science ®Google Scholar